Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG
Go back to Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 200.05 +0.09 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.96 | 52 Week High | $333.65 | |||
| Open | $200.57 | 52 Week Low | $223.02 | |||
| Day High | $203.45 | P/E | 25.61 | |||
| Day Low | $199.06 | EPS | $7.81 | |||
| Volume | 837,294 | |||||
